Academic Unit of Obstetrics and Gynecology, DINOGMI Department, University of Genova, Genova, Italy.
U.O.S. Physiopathology of Human Reproduction, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Gynecol Endocrinol. 2020 Dec;36(12):1074-1078. doi: 10.1080/09513590.2020.1737668. Epub 2020 Mar 9.
This study aims at detecting and evaluating differences in quantitative response to controlled ovarian stimulation (COS) with high doses of gonadotropins in women with low serum anti-Müllerian hormone (AMH). About 369 first cycles in a real-life scenario in women between 21 and 43 years old and with AMH ≤0.9 ng/ml were analyzed. Older women had a significantly worse outcome with respect to young women, not only qualitatively, but also in terms of quantitative ovarian response to COS [odd ratio (OR) to obtain at least three MII oocytes with each increasing year of female age: 0.89, 95% CI: 0.85 - 0.94; < .001]. This study endorses that age is a significant factor when counseling patients with low AMH. AMH levels are not a reason to exclude patients from a COS treatment, since pregnancy and live birth can be achieved, especially in younger patients. However, with an AMH equally low, the ovarian response worsens with age, making questionable the effectiveness of a stimulation with high-dose gonadotropins in the older subgroup.
本研究旨在检测和评估低血清抗苗勒管激素(AMH)水平的女性对大剂量促性腺激素控制性卵巢刺激(COS)的定量反应差异。对 369 名年龄在 21 至 43 岁之间且 AMH≤0.9ng/ml 的女性的真实场景中的首次周期进行了分析。与年轻女性相比,老年女性的结局无论是定性的还是定量的卵巢对 COS 的反应都明显更差[获得至少三个成熟 II 期卵子的比值比(OR):每增加一年女性年龄:0.89,95%CI:0.85-0.94; < .001]。这项研究证实,年龄是对低 AMH 患者进行咨询时的重要因素。AMH 水平并不是将患者排除在 COS 治疗之外的原因,因为可以实现妊娠和活产,尤其是在年轻患者中。然而,在 AMH 同样低的情况下,随着年龄的增长,卵巢反应会恶化,这使得在年龄较大的亚组中使用高剂量促性腺激素刺激的效果值得怀疑。